Big News Roundup: Provincial Environmental Assessment Review Of IDM Mining’s Red Mountain Gold Project Advances To Final Stage; M2 Cobalt Discovers Extensive Mineralization at Bujagali; Neo Lithium Provides Resource Estimate Update for its 3Q Lithium Project with a 227% Increase in Measured and Indicated Categories

In case you missed it, here is this week's big news roundup.

Spectral Announces Successful Manufacturing Audit of Toray by the US FDA

Spectral Medical (TSX:EDT) has announced that Toray Industries has successfully passed a GMP Audit with the US FDA. As quoted...

What Is In-Licensing?

Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions. Read on...

4 Top Pharma Stocks on the TSX Year-to-Date

As investors look ahead to the remainder of 2018, we've put together a list of the top-gaining pharmaceutical stocks on...

Advantage Lithium Commences Preliminary Economic Assessment and Phase III Resource Conversion Program for the Cauchari Definitive Feasibility Study

Advantage Lithium Corp (TSXV:AAL; OTCQX:AVLIF) is pleased to announce that is has engaged WorleyParsons Chile S.A. (WP) to complete a...

Big News Roundup: Osprey Commences Exploration Program at Caribou Gold Project; ML Gold Completes First 689 Metre Hole at Stars Property; Azincourt Energy Adds Lithman East Extension to Its Lithium Project Portfolio with New Age Metals

In case you missed it, here is this week's big news roundup.

U.S. FDA Clears Pluristem’s Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery

Pluristem Therapeutics (Nasdaq:PSTI) a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA)...

SilverCrest Delineates 10th High-Grade Vein at Las Chispas

SilverCrest Metals Inc. announced drill results from the Luigi vein on the Las Chispas property located in Sonora, Mexico.

Data Monitoring Committee Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the independent Data Monitoring Committee (DMC) for the Company’s...

Is this the Next Botox? Evolus’s Phase 3 Study Met Primary Endpoints

Botox has long been one the best solutions for smoothing wrinkle lines, managing skin breakouts, lifting lips and more, but...